The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Abstract Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan, Pao-Hsien Chu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-11-01
coleção:	Cardiovascular Diabetology
Assuntos:	Atrial fibrillation Type 2 diabetes mellitus Sodium glucose cotransporter-2 inhibitor Dipeptidyl peptidase-4 inhibitor Heart failure
Acesso em linha:	http://link.springer.com/article/10.1186/s12933-020-01162-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!